文献速递哮喘

韩国重症哮喘患者的急性加重相关负担:一项基于人群的队列研究

Exacerbation-related burden in patients with severe asthma in South Korea: a population-based cohort study
RSS 订阅 · BMJ Open Respiratory Research

该研究利用2016至2019年韩国国民健康保险数据开展回顾性队列研究,评估重症哮喘患者急性加重相关负担。结果显示门诊就诊占所有加重事件的81.26%,加重相关费用从门诊29.89美元至ICU 7918.86美元不等,病死率在哮喘患者中为2.65%、有加重者为3.16%、加重且住院者为6.96%。

要点

  • 门诊就诊占重症哮喘加重事件的81.26%,其次为普通病房住院(14.55%)。
  • 加重相关费用:门诊29.89美元、急诊95.02美元、普通病房1929.32美元、ICU 7918.86美元。
  • 病死率:哮喘患者2.65%,有加重者3.16%,加重且住院者6.96%。

核心结论

  • 本研究是首个利用近期数据观察韩国重症哮喘患者急性加重相关负担的基于人群的队列研究,可提供真实世界证据。

研究设计与样本

  • 回顾性队列研究,使用2016至2019年韩国国民健康保险数据。
  • 重症哮喘定义为:有哮喘诊断且处方≥1种吸入性皮质激素-长效β2受体激动剂和长效毒蕈碱拮抗剂;并在满足上述条件后1年内经历≥4次哮喘加重事件。
  • 加重定义为需要皮质类固醇冲击治疗。

主要发现

  • 门诊就诊占所有加重事件的81.26%,普通病房住院占14.55%。
  • 加重相关费用:门诊29.89美元,急诊95.02美元,普通病房住院1929.32美元,ICU入住7918.86美元。
  • 病死率:哮喘患者2.65%,有加重者3.16%,有加重且住院者6.96%。

关键数值与推荐

  • 重症哮喘定义要求处方≥1种吸入性皮质激素-长效β2受体激动剂和长效毒蕈碱拮抗剂,且1年内≥4次加重事件。
  • 加重定义为需要皮质类固醇冲击治疗。

临床怎么用

  • 研究结果可用于哮喘负担的进一步研究,并为医疗政策决策提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background The burden of severe asthma due to asthma exacerbation is increasing. However, recent studies identifying exacerbation-related disease burden among patients with severe asthma in South Korea are lacking. Objective To evaluate the burden of asthma exacerbations in patients with severe asthma in South Korea. Methods A retrospective cohort study using National Health Insurance data from 2016 to 2019 was conducted. Patients with severe asthma were defined as satisfying the following criteria: (1) having been prescribed ≥1 inhaled corticosteroid-long-acting β-2 agonist and long-acting muscarinic antagonist with a diagnosis of asthma; (2) having experienced ≥4 asthma exacerbation events within 1 year, after meeting the first criterion. Exacerbation was defined as a corticosteroid burst. Healthcare utilisation, direct medical costs and case fatality rates related to asthma exacerbations were identified during the follow-up period. Results Outpatient visits accounted for 81.26% of all exacerbation events, followed by general ward hospitalisation (14.55%). The exacerbation-related costs were as follows: outpatient visit, $29.89; emergency room visit, $95.02; general ward hospitalisation, $1929.32; and intensive care unit admission, $7918.86. The case fatality rates were 2.65% for patients with asthma, 3.16% for patients who had exacerbations and 6.96% for patients who had exacerbations with hospitalisation. Conclusion This study is the first population-based cohort study observing exacerbation-related burdens in patients with severe asthma, using recent data and generating real-world evidence. The results of this study can be used as evidence for further research on the burden of asthma and to inform decision-making in healthcare policy.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Exacerbation-related burden in patients with severe asthma in South Korea: a population-based cohort study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。